A Phase I Study of Oral BGJ398 in Asian Patients With Advanced Solid Tumor Having Alterations of the FGF-R Pathway
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Infigratinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 22 Dec 2017 Planned End Date changed from 7 Dec 2017 to 7 Dec 2018.
- 22 Dec 2017 Planned primary completion date changed from 7 Dec 2017 to 7 Dec 2018.
- 22 Dec 2017 Status changed from recruiting to active, no longer recruiting.